Project Grant R21AI184073
Award Date
8/6/24
Completion Date
7/31/26
Dollars Obligated
$251K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is supporting a study of acute HIV infection to investigate strategies for HIV eradication. The $794,045 award to The Regents of the University of California, San Francisco (UCSF) aims to identify host cellular mechanisms that drive HIV reservoir decay and sustained viral control, with the goal of informing...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a study to investigate the role of cytokines IL-10 and IFN in controlling the HIV reservoir and achieving functional cure. The total funding amount is $856,202 over the period of November 15, 2024 to October 31, 2029. The principal investigator and awardee is The Regents of the University of California, San...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,617,200 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Arizona to conduct research on immune microenvironments that impact HIV persistence and expression during antiretroviral therapy (ART). The key objectives of this 5-year research project are to: 1) Determine the location, phenotype, and microenvironment of HIV RNA expressing cells in secondary lymphoid...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is funding research to characterize the HIV latent reservoir and understand the mechanisms driving its persistence in people living with HIV on antiretroviral therapy. The $234,115 award will support in-depth sequencing of intact and defective HIV proviruses to map the clonal distribution of infected cells, as well as...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,314,572 to Yale University to develop and translate small-molecule CD4-mimetic compounds (CD4MCs) as a cure strategy for HIV-1. The project aims to investigate physiological variables that facilitate effective reservoir elimination using CD4MC/antibody (CD4MC/AB) interventions in humanized mouse models, formulate a...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $128,250.00 to support the development of anti-PD-1-targeted chimeric antigen receptor (CAR) and genetic circuit technologies to deplete viral reservoirs in a nonhuman primate model of lentiviral infection, with the goal of advancing efforts towards an HIV cure. The key objectives are to engineer a more specific and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,688,880.00 to Emory University to evaluate the safety and therapeutic potential of a novel strategy to achieve sustained HIV remission. The key products and services to be delivered under this award include: Conducting comprehensive studies to assess how a combination therapy of IL-15/IL-15RA and TGF-beta pathway...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $781,367 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Weill Medical College of Cornell University. The grant, awarded on January 25, 2024, will support research to define and maximize the impact of CD8+ T-cell selection on the landscape of HIV integration sites. The goal is to optimize strategies for eradicating the persistent reservoir of HIV-infected cells and achieve...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research aimed at investigating the role of the protein galectin-9 in HIV persistence and the establishment of the long-term viral reservoir. The total funding amount is $775,391.00, with a project period from August 1, 2024 to June 30, 2029. The research team, led by investigators at Vitalant Research...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $499,550.00 to The Washington University in Missouri to conduct research on controlling the long-lived HIV cellular reservoir in memory CD4+ T cells. The research aims to understand how the BACH2 gene inhibits the terminal differentiation of CCR5+ CD4+ T cells, which are the primary targets for HIV infection and...